For the Inventor, By the Inventor

Enter assignee name

Tel Aviv, Israel

Redhill Biopharma Ltd.

USPTO Granted Patents = 40

CIPO Patents = 25

EPO Patents = 6

Trademarks = 13

Forward Citations = 56

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Reza Fathi (31 out of 40 patents)

Patrick Gosselin (16 out of 20 patents)

Dror Ben-Asher (15 out of 15 patents)

4. Guy Goldberg (14 out of 14 patents)

5. Gilead Raday (11 out of 11 patents)

6. Thomas Julius Borody (9 out of 111 patents)

7. Danielle Abramson (4 out of 4 patents)

8. Patrick Laughlin Mclean (2 out of 2 patents)

9. Ofra Barnett (2 out of 2 patents)

10. Patrick Laughlin McLean (1 out of 2 patents)

11. Mark L Levitt (1 out of 2 patents)

12. Patricia Anderson (1 out of 1 patent)

13. Elliot Offman (1 out of 1 patent)

14. Harry Jefferson Leighton (1 out of 11 patents)

15. Joanne Speed (1 out of 1 patent)

Core Competencies:

Single-Stranded RNA Virus

Coronavirus Infection

Sphingosine Kinase 2 Inhibitor

Serine Protease Inhibitor

Fixed-Dose Combination

Cancer Treatment

Ebola Virus Treatment

Helicobacter Pylori Infection

Colonic Evacuation

Irritable Bowel Syndrome

Triple Antibiotic Therapy

Autoimmune Disease Treatment

40 patents: Sort by Forward Citations

1. 12370206 - Therapy for inhibition of single-stranded RNA virus replication (2025-07-29),

2. 12115150 - Biomarkers of coronavirus pneumonia (2024-10-15),

3. 11931463 - All-in-one fixed-dose combination for treatinginfection (2024-03-19),

4. 11918560 - Serine protease inhibitor for treating coronavirus infection (2024-03-05),

5. 11878011 - Method for eradicatinginfection in patients regardless of body mass index (2024-01-23),

6. 11786541 - Inhibitor of sphingosine kinase 2 for treating Ebola (2023-10-17),

7. 11633385 - Combination compositions for treatment of cancer (2023-04-25),

8. 11590154 - Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections (2023-02-28),

9. 11471448 - Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia (2022-10-18),

10. 11364227 - Sphingosine kinase 2 inhibitor for treating coronavirus infection (2022-06-21),

11. 11135172 - Rifabutin-based compositions and methods for treatinginfection (2021-10-05),

12. 11090326 - Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine (2021-08-17),

13. 11090325 - Compositions for treating ebola virus infection (2021-08-17),

14. 11058671 - Formulations and methods of manufacturing formulations for use in colonic evacuation (2021-07-13),

15. 11052073 - Sphingosine kinase 2 inhibitor for treating coronavirus infection (2021-07-06),

RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of innovative gastrointestinal products. They specialize in targeted therapies for gastrointestinal diseases and are committed to improving patients' lives by providing effective treatment options. RedHill Biopharma's goal is to rapidly advance its pipeline of proprietary drugs and improve patient outcomes in areas of unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

40 Patents

#20 in Tel Aviv

#119 in Israel

#16,545 in the World

Tel Aviv, Israel

Redhill Biopharma Ltd.

Forward Citations = 56

24 inventors:

Reza Fathi (31 out of 40 patents)

Patrick Gosselin (16 out of 20 patents)

Dror Ben-Asher (15 out of 15 patents)

4. Guy Goldberg (14 out of 14 patents)

5. Gilead Raday (11 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…